132 related articles for article (PubMed ID: 27147621)
1. Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study.
Kuhn A; Landmann A; Patsinakidis N; Ruland V; Nozinic S; Perusquía Ortiz AM; Sauerland C; Luger T; Tsianakas A; Bonsmann G
Lupus; 2016 Oct; 25(12):1357-64. PubMed ID: 27147621
[TBL] [Abstract][Full Text] [Related]
2. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
[TBL] [Abstract][Full Text] [Related]
4. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy.
Kreuter A; Tomi NS; Weiner SM; Huger M; Altmeyer P; Gambichler T
Br J Dermatol; 2007 Jun; 156(6):1321-7. PubMed ID: 17408395
[TBL] [Abstract][Full Text] [Related]
6. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus.
Kuhn A; Meuth AM; Bein D; Amler S; Beissert S; Böhm M; Brehler R; Ehrchen J; Grundmann S; Haust M; Ruland V; Schiller M; Schulz P; Ständer S; Sauerland C; Köpcke W; Luger TA; Bonsmann G
Br J Dermatol; 2010 Jul; 163(1):83-92. PubMed ID: 20394621
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
Wenzel J; Brähler S; Bauer R; Bieber T; Tüting T
Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342
[TBL] [Abstract][Full Text] [Related]
8. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
[TBL] [Abstract][Full Text] [Related]
9. Severe recalcitrant cutaneous manifestations in systemic lupus erythematosus successfully treated with fumaric acid esters.
Saracino AM; Orteu CH
Br J Dermatol; 2017 Feb; 176(2):472-480. PubMed ID: 27105770
[TBL] [Abstract][Full Text] [Related]
10. The classification and diagnosis of cutaneous lupus erythematosus.
Kuhn A; Landmann A
J Autoimmun; 2014; 48-49():14-9. PubMed ID: 24486120
[TBL] [Abstract][Full Text] [Related]
11. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
[TBL] [Abstract][Full Text] [Related]
13. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.
Kuhn A; Sigges J; Biazar C; Ruland V; Patsinakidis N; Landmann A; Amler S; Bonsmann G;
Br J Dermatol; 2014 Sep; 171(3):571-9. PubMed ID: 24673427
[TBL] [Abstract][Full Text] [Related]
14. Acitretin treatment in antimalarial-refractory/intolerant discoid lupus erythematosus: A prospective, open-label, uncontrolled study.
Laosakul K; Chiewchanvit S; Chuamanochan M; Tovanabutra N
Lupus; 2022 Apr; 31(5):575-581. PubMed ID: 35306922
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus.
Sigges J; Biazar C; Landmann A; Ruland V; Patsinakidis N; Amler S; Bonsmann G; Kuhn A;
Autoimmun Rev; 2013 May; 12(7):694-702. PubMed ID: 23220353
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study Characterizing Factors in Adherence to Cutaneous Lupus Treatment.
Ro T; Tull RZ; Cardwell LA; Farhangian ME; Moustafa F; Richardson I; Jorizzo JL; Feldman S; Huang W
J Cutan Med Surg; 2018; 22(5):530-532. PubMed ID: 30168386
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
[TBL] [Abstract][Full Text] [Related]
18. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.
Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R
Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966
[TBL] [Abstract][Full Text] [Related]
19. [Resistant and progressive cutaneous lupus erythematosus treated with belimumab: A retrospective monocentric study].
Dresco F; Puzenat E; Delobeau M; Salard D; Lihoreau T; Pelletier F; Aubin F
Rev Med Interne; 2020 Mar; 41(3):152-159. PubMed ID: 31980188
[TBL] [Abstract][Full Text] [Related]
20. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
